Home
Resources
Diseases
Compendium
Training
Evaluation
The Tool
The Tutorial
The Dashboard
SYSVAC
About
Registry
E-learning courses
News
Webinars
Network
Steering Committee
Vision and Mission
Map
Meetings
Partners
Join us
Home
Resources
Resources
Type of publications
Guidelines (31)
NITAG documentation (1595)
Reports (56)
SAGE documentation (225)
Scientific publications (112)
Systematic reviews (SYSVAC) (2853)
Regions
Africa (275)
Americas (766)
Eastern Mediterranean (50)
Europe (707)
South-East Asia (81)
Western Pacific (200)
Diseases
Chikungunya (9)
Cholera (34)
COVID-19 (1513)
Cytomegalovirus (1)
Dengue (40)
Diphtheria (80)
Ebola (16)
Escherichia coli (ETEC) (2)
Haemophilus influenzae type B (68)
Hepatitis A (64)
Hepatitis B (157)
Hepatitis C (4)
Hepatitis E (5)
Herpes simplex (1)
Herpes zoster (69)
HIV / AIDS (10)
Human papillomavirus (HPV) (493)
Influenza (581)
Japanese encephalitis (34)
Lyme disease, Borreliosis (1)
Malaria (28)
Measles (131)
Meningococcal disease (148)
Moraxella catarrhalis (1)
Mpox (55)
Mumps (46)
Pertussis (105)
Pneumococcal disease (277)
Poliomyelitis (86)
Q fever (1)
Rabies (29)
Rotavirus (117)
RSV (Respiratory syncytial virus) (50)
Rubella (64)
Salmonella (3)
Shigella (1)
Smallpox (16)
Streptococcus group B (6)
Tetanus (60)
Tick-borne encephalitis (12)
Tuberculosis (77)
Typhoid (24)
Varicella (71)
Yellow fever (42)
Zika (1)
Show more
4872 results found
2022
∙
SAGE
Interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19
2022
∙
SAGE
Background document on the Cansino Ad5-nCoV-S vaccine (Convidecia ®) against COVID-19
2022
∙
SAGE
Annexes to the interim recommendations for use of the Cansino Ad5-nCoV-S vaccine (Convidecia ®) against COVID-19
2022
∙
SAGE
Background document on the Valneva VLA2001 vaccine against COVID-19
2022
∙
SAGE
Annexes to the interim recommendations for use of the Valneva VLA2001 vaccine against COVID-19
2022
∙
SAGE
Malaria vaccine: WHO position paper
2022
Niger-NITAG advice on the introduction of the malaria vaccine in routine immunization
2022
∙
Conseil Supérieur de la Santé (CSS)
Vaccination against pneumococcal disease for adults in Belgium
2022
∙
NACI
Recombinant influenza vaccines: A supplemental statement of the Canadian Immunization Guide chapter on influenza and statement on seasonal influenza vaccine for 2022–2023
2022
∙
NACI
Recommendations on the use of bivalent Omicroncontaining mRNA COVID-19 vaccines
Home
Resources
Diseases
Compendium
Training
Evaluation
SYSVAC
News
Webinars
Network
Sign in / Register